NewTimeSpace News: On 17 August 2026, HUTCHMED (00013.HK) announced positive topline results from the SAFFRON Phase III study of ORPATHYS® plus TAGRISSO® in MET-driven EGFR-mutated NSCLC, showing statistically significant and clinically meaningful improvements in both PFS and OS, the first global Phase III trial in this setting to show significant benefit on both endpoints; the combination was well tolerated, and the data will be shared with global regulatory authorities to support global registration of the regimen.
NewTimeSpace News: CanSino Biologics announced on August 16 that the new drug application (NDA) for its self-developed adsorbed acellular (five-component) diphtheria-tetanus-pertussis combined vaccine for adolescents and adults, Td5cp, has been accepted for review by the National Medical Products Administration (NMPA).
On August 14, 2026, Hong Kong's three major indices all weakened collectively. The Hang Seng Index fell 1.10%, the Hang Seng TECH Index fell 1.77%, and the Hang Seng China Enterprises Index fell 1.02%.AI concept stocks saw sharp intraday volatility that day, with many names retreating across the board after rallying in early trading.The AI chip segment showed clear divergence. SMIC (00981.HK), buoyed by better-than-expected second-quarter results, closed up 4.81%, while GIGADEVICE (03986.HK) rose 2.00%. HUA HONG GRACE (01347.HK), by contrast, fell nearly 12% on weaker-than-expected third-quarter revenue guidance, with BIREN TECH and MONTAGE TECHNOLOGY also softening.
NewTimeSpace News: On 14 August 2026, XPENG-W (09868.HK) edged higher in the afternoon session, closing at HK$45.52, representing a gain of 0.31%.
newtimespace (newtimespace.com) reported, on August 14, 2026, the chip theme pulled back amid volatility, with HUA HONG GRACE (01347.HK) weakening sharply. As of 13:26, the stock was quoted at HK$128.400, down 12.77%.
newtimespace (newtimespace.com) reported, on August 14, 2026, the robotics theme lost momentum, with MIDEA GROUP (00300.HK) fluctuating lower. As of 13:19, the stock was quoted at HK$96.150, edging down 0.26%.
NewTimeSpace News: On 13 August 2026, GBA AI COMP (01396.HK) announced that Shenzhen Hongrui, an indirect non-wholly-owned subsidiary, entered into finance lease agreements with SPDB Financial Leasing to sell and lease back IT equipment and ancillary equipment at an aggregate purchase price of approximately RMB 1.687 billion, with lease terms of 61 to 62 months and total lease payments of approximately RMB 1.921 billion, to support the delivery of AI computing power cloud services orders. The Group recorded new intention orders for AI computing power cloud services of over RMB 15 billion in H1 2026 (over RMB 4 billion delivered as of the announcement date) and a further over RMB 7 billion since July; the transaction constitutes a discloseable transaction exempt from shareholders' approval.
NewTimeSpace News: On 13 August 2026, LONGCHEER (09611.HK) announced that it entered into four share transfer agreements with the sellers to acquire 80% of Suzhou Anruike Information Technology Co., Ltd., a data centre infrastructure provider, for a total consideration of RMB 1,120.00 million, with the target becoming a non-wholly-owned subsidiary upon completion. The 100% equity interest of the target was valued at RMB 1,509.00 million (an appreciation of 424.98%), with profit guarantors providing earnings commitments and compensation arrangements; the transaction constitutes a discloseable transaction without circular and shareholders' approval, and is not a connected transaction.
NewTimeSpace News: On 14 August 2026, FUTURE MACH LTD (01401.HK) announced that its indirect wholly-owned subsidiary Shenzhen Xingji Quantum will participate in the fourth angel round capital increase of Zhichen Semiconductor (Shenzhen) Co., Ltd. at a subscription price of RMB 20 million for new registered capital of RMB 50,073.57, resulting in an indirect interest of approximately 0.9742% upon completion. The target company had completed three earlier angel rounds raising an aggregate of RMB 369.68 million; the funding comes from the approximately HKD 20 million strategic investment portion of rights issue proceeds, and the transaction constitutes a discloseable transaction exempt from the circular and shareholders' approval.
On August 13, 2026, the three major Hong Kong stock indices were mixed, with the technology theme strengthening. The Hang Seng Index edged down 0.17%, the Hang Seng TECH Index rose 0.33%, and the Hang Seng China Enterprises Index edged down 0.23%.In the large-model segment, performance diverged; the two leaders continued to strengthen. The MSCI China Index newly added Z.AI (02513.HK), which rose 9.02%; MINIMAX-W (00100.HK) rose 5.43%; Baidu Group-SW edged up; while Alibaba-W, Kuaishou-W and others weakened.
NewTimeSpace News, on August 13, 2026, the chip theme continued to strengthen, with ASMPT (00522.HK) fluctuating higher. As of 13:28, the company's quote stood at HKD 178.400, up 5.25%.
NewTimeSpace News, on August 13, 2026, the robot theme saw volatile trading, with XIAOMI-W (01810.HK) opening lower and trending weaker. As of 13:12, the company's quote stood at HKD 26.200, down a slight 0.61%.
NewTimeSpace News: On 12 August 2026, AKESO (09926.HK) announced that the NMPA has approved the sNDA for its first-in-class bispecific antibody Ivonescimab (PD-1/VEGF) plus chemotherapy for the first-line treatment of advanced squamous NSCLC (sq-NSCLC), the third approved indication of Ivonescimab. The approval is based on the positive results of the Phase III study HARMONi-6: median OS of 27.89 versus 23.69 months (HR=0.66) and median PFS of 11.1 versus 6.9 months (HR=0.60), with positive interim OS and PFS results presented at the ASCO and ESMO Plenary Sessions respectively.
NewTimeSpace News: On 13 August 2026, UNISOUND (09678.HK) announced the official release of its self-developed medical imaging multimodal large model U2-RadiMed, the first full-chain imaging large model in China covering CXR, CT, MRI and other imaging modalities; the model ranked first in the general comprehensive assessment with a composite score of 55.47, ahead of Gemini 3.1 and GPT-5.4, and first among participating models in the MedBench 5.0 assessment with 57.2. The model has been launched on the MaaS platform (Token Hub), supporting multi-image input and a 40K context window.
NewTimeSpace News: On 12 August 2026, HENGRUI PHARMA (01276.HK) disclosed that its subsidiary Guangdong Hengrui received the Drug Clinical Trial Approval Notice for SHR-7590 Injection, approving clinical trials for ulcerative colitis and Crohn's disease; the drug is an in-house developed therapeutic biologic with no same-target drug approved globally, and cumulative R&D investment of approximately RMB 32.5 million.
NewTimeSpace News: On 12 August 2026, HENGRUI PHARMA (01276.HK) disclosed that HRS-4729 Injection, an in-house developed GLP-1R/GIPR/GCGR tri-agonist polypeptide, received NMPA approval for a Phase II clinical trial in adult type 2 diabetes patients, with a Phase II trial for weight loss also being advanced, and cumulative R&D investment of approximately RMB 81.6 million.
